Our Vision
Create a world where no life is cut short by cancer or other serious diseases.
Our Science
Medicines that reach traditionally hard-to-reach targets.
Transcription factors have long been attractive to drug developers, who historically have pursued them in isolation with little success. Our approach: pursue the transcription factors in context, within their transcriptional regulatory networks (TRNs). By analyzing the TRN in its entirety, we identify the critical nodes that are responsible for a transcription factor’s activity. This provides multiple avenues to pursue, rather than limiting our focus on a single transcription factor.
Our Pipeline
Istisociclib, a CDK9 inhibitor, was being evaluated in a Phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as ovarian cancer. A second development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma and HPV-driven tumors. A third development candidate, KB-7898, is a p300 KAT inhibitor for the potential treatment of Sjögren’s disease.
